Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus SOX and camrelizumab as neoadjuvant therapy in locally advanced gastric cancer
ChiCTR2200062285Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib, tegafur, oxaliplatin and camrelizumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by West China Hospital of Sichuan University. Primary endpoint: Major pathological remission (MPR). Planned start Aug 2022; status: not yet recruiting.
02
Drugs
Rivoceranibtegafuroxaliplatincamrelizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200062285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062285.